Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Published:2016-09-24 Issue:2 Volume:8 Page:3581-3590
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Fendler Wolfgang P.¹²,Reinhardt Svenja¹,Ilhan Harun¹,Delker Andreas¹,Böning Guido¹,Gildehaus Franz J.¹,Stief Christian³⁴,Bartenstein Peter¹⁴,Gratzke Christian³⁴,Lehner Sebastian¹,Rominger Axel¹

Affiliation:

1. Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Munich, Germany

2. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

3. Department of Urology, Ludwig-Maximilians-University of Munich, Munich, Germany

4. Comprehensive Cancer Center, Ludwig-Maximilians-University of Munich, Munich, Germany

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 186 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer;European Journal of Radiology;2024-11

2. Impact of Posttreatment SPECT/CT on Patient Management During¹⁷⁷Lu-PSMA-617 Radiopharmaceutical Therapy;Journal of Nuclear Medicine;2024-08-08

3. Tubarial salivary glands show a low relative contribution to functional salivary gland tissue mass;Annals of Nuclear Medicine;2024-07-26

4. A review of 177Lu dosimetry workflows: how to reduce the imaging workloads?;EJNMMI Physics;2024-07-18

5. Organ and tumor dosimetry including method simplification for [177Lu]Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer;EJNMMI Physics;2024-07-17